Advertisement

World Journal of Surgery

, Volume 42, Issue 11, pp 3624–3631 | Cite as

The Updated AJCC/TNM Staging System for Papillary Thyroid Cancer (8th Edition): From the Perspective of Genomic Analysis

  • Kyubo Kim
  • Jin Hwan Kim
  • Il Seok Park
  • Young Soo Rho
  • Gee Hwan Kwon
  • Dong Jin Lee
Original Scientific Report

Abstract

Background

Recently, the American Joint Committee on Cancer published the 8th edition of its Cancer Staging Manual with major changes regarding the staging of thyroid cancer, including the raising of the age cutoff from 45 to 55 years. Using the clinical and genetic data of 505 papillary thyroid cancer (PTC) cases, we aimed to compare overall survival (OS) and recurrence-free survival (RFS) with different age cutoff values, and also investigate the efficacy of the new staging system on a genomic level.

Methods

We downloaded gene expression data, somatic mutation profile, copy number alteration data and clinical data of 505 PTC patients from The Cancer Genome Atlas data portal. We used multiple statistical analysis and multiplatform genomic analysis to evaluate the efficacy of the 8th edition.

Results

When using 55 years as the cutoff value for analyzing RFS, the Kaplan–Meier plot showed a significant p value but not when using 45 years (p = 0.006 vs. p = 0.493), but both cutoff values were significant when analyzing OS (p = 1.1 × 10−9 with age 55 vs. p = 4.4 × 10−5 with age 45). When looking at stage-dependent survival, both the 7th and 8th edition had significant p values (p = 0.048 vs. p = 3.1 × 10−9 in RFS and p = 5.9 × 10−10 vs. p = 2.2 × 10−10 in OS). Multiplatform genomic analysis showed patients ≥55 years had 103 differently expressed genes when compared with other age groups. Signaling pathway analysis revealed that patients ≥55 years had altered pathways associated with aggressiveness of thyroid cancer.

Conclusion

In conclusion, this is the first study to show clinical and genetic evidence supporting the altered age cutoff point of 55 years in the AJCC 8th edition for PTC patients.

Notes

Acknowledgements

We appreciate the patients and their families who generously donated their tissues to TCGA, as well as the members of TCGA who collected and disclosed valuable data.

Funding

This research was supported by Hallym University Research Fund 2018 (H20180239).

Compliance with ethical standards

Conflict of interest

All authors have no conflict of interest to declare.

Supplementary material

268_2018_4662_MOESM1_ESM.xlsx (333 kb)
Supplementary material 1 (XLSX 332 kb)
268_2018_4662_MOESM2_ESM.xlsx (13 kb)
Supplementary material 2 (XLSX 13 kb)
268_2018_4662_MOESM3_ESM.xlsx (16 kb)
Supplementary material 3 (XLSX 16 kb)
268_2018_4662_MOESM4_ESM.xlsx (3.2 mb)
Supplementary material 4 (XLSX 3286 kb)

References

  1. 1.
    Siegel R, Ward E, Brawley O et al (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212–236CrossRefGoogle Scholar
  2. 2.
    Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295:2164–2167CrossRefGoogle Scholar
  3. 3.
    Edge SB, Compton CC (2010) The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471–1474CrossRefGoogle Scholar
  4. 4.
    Perrier ND, Brierley JD, Tuttle RM (2018) Differentiated and anaplastic thyroid carcinoma: major changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 68:55–63CrossRefGoogle Scholar
  5. 5.
    LA Simor R, Li MC, Ngan M, Menenzes S, Zhao Y (2007) Analysis of gene expression data using BRB-array Tools. Cancer Inform 4(7): 11–21Google Scholar
  6. 6.
    Eisen MB, Spellman PT, Brown PO et al (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95(8): 14863–14866CrossRefGoogle Scholar
  7. 7.
    Cady B, Rossi R (1988) An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 104(3): 947–995PubMedGoogle Scholar
  8. 8.
    Hay ID, Bergstralh EJ, Goellner JR et al (1993) Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050–1057 (discussion 1057–1058) PubMedGoogle Scholar
  9. 9.
    Shaha AR, Loree TR, Shah JP (1994) Intermediate-risk group for differentiated carcinoma of thyroid. Surgery 116:1036–1040 (discussion 1040–1031) PubMedGoogle Scholar
  10. 10.
    Kim H, Jung HJ, Lee SY et al (2016) Prognostic factors of locally invasive well-differentiated thyroid carcinoma involving the trachea. Eur Arch Oto-Rhino-Laryngol 273(6): 1919–1920CrossRefGoogle Scholar
  11. 11.
    Moritani S (2015) Surgical management of cricotracheal invasion by papillary thyroid carcinoma. Ann Surg Oncol 22:4002–4007CrossRefGoogle Scholar
  12. 12.
    Hotomi M, Sugitani I, Toda K et al (2012) A novel definition of extrathyroidal invasion for patients with papillary thyroid carcinoma for predicting prognosis. World J Surg 36:1231–1240.  https://doi.org/10.1007/s00268-012-1518-z CrossRefPubMedGoogle Scholar
  13. 13.
    Kweon KH, Lee CR, Jung SJ et al (2014) Sirt1 induction confers resistance to etoposide-induced genotoxic apoptosis in thyroid cancers. Int J Oncol 45:2065–2075CrossRefGoogle Scholar
  14. 14.
    Qu N, Hu JQ, Liu L et al (2017) SIRT6 is upregulated and associated with cancer aggressiveness in papillary thyroid cancer via BRAF/ERK/Mcl1 pathway. Int J Oncol 50:1683–1692CrossRefGoogle Scholar
  15. 15.
    Gu Y, Liu X, Yu Y et al (2014) Association of ATM Gene Polymorphism with PTC Metastasis in Female Patients. Int J Endocrinol 2014:370825CrossRefGoogle Scholar
  16. 16.
    Kang J, Deng XZ, Fan YB et al (2014) Relationships of FOXE1 and ATM genetic polymorphisms with papillary thyroid carcinoma risk: a meta-analysis. Tumour Biol 35:7085–7096CrossRefGoogle Scholar
  17. 17.
    Giaginis C, Tsoukalas N, Alexandrou P et al (2017) Clinical significance of farnesoid X receptor expression in thyroid neoplasia. Future Oncol 13(2): 1785–1790CrossRefGoogle Scholar
  18. 18.
    Steinschneider M, Muallem Kalmovich L, Koren S, et al (2017) Reassessment of differentiated thyroid cancer patients using the 8th TNM classification system: a comparative study Thyroid: Official Journal of the American Thyroid Association 2017Google Scholar
  19. 19.
    Lamartina L, Grani G, Arvat E, et al (2017) 8th edition of AJCC/TNM staging system of thyroid cancer: what to expect Endocrine-related cancer 2017Google Scholar
  20. 20.
    Suh S, Kim YH, Goh TS et al (2017) Outcome prediction with the revised American joint committee on cancer staging system and American thyroid association guidelines for thyroid cancer. Endocrine 58(2): 495–450CrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2018

Authors and Affiliations

  • Kyubo Kim
    • 1
  • Jin Hwan Kim
    • 1
  • Il Seok Park
    • 1
  • Young Soo Rho
    • 1
  • Gee Hwan Kwon
    • 1
  • Dong Jin Lee
    • 1
  1. 1.Department of Otorhinolaryngology-Head and Neck SurgeryHallym University College of MedicineSeoulSouth Korea

Personalised recommendations